• Azitra announced ex vivo results showing its ATR-COSF cosmetic candidate reduced the appearance of fine lines and wrinkles in human skin samples.
• The higher-concentration formulation improved skin elasticity compared with the lower concentration and hydrogel control.
• A first-in-human study is planned in approximately 30 participants, with initial results expected by year-end 2026.
• Detailed ex vivo results will be presented at BIO-Europe in Cologne, Germany, on November 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY80453) on October 26, 2026, and is solely responsible for the information contained therein.